Journals / Bağcılar Tıp Bülteni / 2022 / Cilt: 7 - Sayı: 2

Clinicopathological Features and Prognostic Factors in Patients with Small Bowel Adenocarcinoma

İnce Bağırsak Adenokarsinomlu Hastalarda Klinikopatolojik Özellikler ve Prognostik Faktörler

Pages
144–149
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The Kaplan-Meier and Cox regression analyses were used to assess overall survival and prognostic factors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Small bowel adenocarcinoma is a rare tumor, and data on prognosis are limited.
📊
Key Findings & Data:Results: The origin sites of the tumor were the duodenum (50%), jejunum (31.8%), and ileum (18.2%), respectively.
💡
Conclusion & Impact:The Kaplan-Meier and Cox regression analyses were used to assess overall survival and prognostic factors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Small bowel adenocarcinoma is a rare tumor, and data on prognosis are limited. We aimed to evaluate the clinicopathological features and prognostic factors in small bowel adenocarcinoma in this study. Method: Twenty-two patients were evaluated. Clinicopathological features and treatment approaches were retrospectively recorded. The Kaplan-Meier and Cox regression analyses were used to assess overall survival and prognostic factors. Results: The origin sites of the tumor were the duodenum (50%), jejunum (31.8%), and ileum (18.2%), respectively. The number of de novo metastatic patients was 11 (50%). The most common metastatic sites were the peritoneum (%45), liver (%41), and lymph nodes (18%). The median overall survival was 19.9 months (7.3-32.5). One- and two-year survival ratios were 65.9% and 39%, respectively. The response ratio (complete or partial) of first-line chemotherapy in metastatic patients was determined as 46.2%. In multivariate analysis, surgery (p=0.024) and age at diagnosis (p=0.017) were statistically significant prognostic factors for overall survival. However, the site of the tumor (p=0.106), de novo metastatic disease (p=0.323), and the number of metastatic sites (p=0.086) were not. Conclusion: Patients with small bowel adenocarcinoma were diagnosed in advanced stages, and the prognosis of the disease was poor. We observed that removing the primary tumor improved survival, and being older than 60 years was a negative prognostic factor.

Özet

Amaç: İnce bağırsak adenokarsinomu nadir görülen bir tümördür ve prognozu ile ilgili veriler sınırlıdır. Bu çalışmada ince bağırsak adenokarsinomlu hastalarda klinikopatolojik özellikleri ve prognostik faktörleri değerlendirmeyi amaçladık. Yöntem: Yirmi iki hasta değerlendirildi. Klinikopatolojik özellikler ve tedavi yaklaşımları retrospektif olarak kaydedildi. Genel sağkalımı ve prognostik faktörleri değerlendirmek için Kaplan-Meier ve Cox regresyon analizleri kullanıldı. Bulgular: Tümörün primer çıkış yerleri sırası ile duodenum (%50), jejunum (%31,8) ve ileum (%18,2) idi. De novo metastatik hasta sayısı 11 (%50) idi. En sık metastatik bölgeler sırası ile periton (%45), karaciğer (%41) ve lenf düğümleri (%18) idi. Medyan genel sağkalım süresi 19,9 aydı (7,3- 32,5) idi. Bir ve iki yıllık sağkalım oranları sırasıyla %65,9 ve %39 olarak bulundu. Metastatik hastalarda birinci basamak kemoterapinin yanıt oranı (tam veya kısmi yanıt) %46,2 olarak tespit edildi. Çok değişkenli analizde cerrahi (p=0,024) ve tanı yaşı (p=0,017) genel sağkalım için istatistiksel olarak anlamlı prognostik faktörler olarak tespit edildi. Ancak primer tümör bölgesi (p=0,106), de novo metastatik hastalık (p=0,323) ve metastatik bölge sayısı (p=0,086) istatistiksel olarak anlamlı değildi. Sonuç: İnce bağırsak adenokarsinomlu hastalara sıklıkla ilerlemiş hastalık ile tanı konulmuştu ve hastalığın prognozu kötüydü. Primer tümörün çıkarılmasının sağkalımı iyileştirdiğini ve tanı sırasında 60 yaşından büyük olmanın olumsuz bir prognostik faktör olduğunu tespit ettik

🔖

Cite This Article

DOĞAN, İ., TAŞTEKİN, D. (2022). Clinicopathological Features and Prognostic Factors in Patients with Small Bowel Adenocarcinoma. Bağcılar Tıp Bülteni, Cilt: 7 - Sayı: 2, 144–149. https://ajindex.com/articles/458875

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Martin RG. Malignant tumors of the small intestine. Surg Clin North Am 1986;66(4):779-785
  2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71(1):7-33
  3. Weiss NS, Yang CP. Incidence of histologic types of cancer of the small intestine. J Natl Cancer Inst 1987;78(4):653-656
  4. Chow WH, Linet MS, McLaughlin JK, Hsing AW, Chien HT, Blot WJ. Risk factors for small intestine cancer. Cancer Causes Control 1993;4(2):163-169
  5. Schottenfeld D, Beebe-Dimmer JL, Vigneau FD. The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol 2009;19(1):58-69
  6. Pedersen KS, Raghav K, Overman MJ. Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. J Natl Compr Canc Netw 2019;17(9):1135-1141
  7. Wu AH, Yu MC, Mack TM. Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. Int J Cancer 1997;70(5):512-517
  8. Kaerlev L, Teglbjaerg PS, Sabroe S, Kolstad HA, Ahrens W, Eriksson M, et al. Is there an association between alcohol intake or smoking and small bowel adenocarcinoma? Results from a European multicenter case-control study. Cancer Causes Control 2000;11(9):791- 797
  9. Emilsson L, Semrad C, Lebwohl B, Green PHR, Ludvigsson JF. Risk of Small Bowel Adenocarcinoma, Adenomas, and Carcinoids in a Nationwide Cohort of Individuals With Celiac Disease. Gastroenterology 2020;159(5):1686-1694.e2
  10. Pedersen KS, Foster NR, Overman MJ, Boland PM, Kim SS, Arrambide KA, et al. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clin Cancer Res 2021;27(13):3641-3648
  11. Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010;199(6):797-803
  12. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004;101(3):518-526
  13. Xiang XJ, Liu YW, Zhang L, Qiu F, Yu F, Zhan ZY, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs 2012;23(5):561- 566
  14. Tsushima T, Taguri M, Honma Y, Takahashi H, Ueda S, Nishina T, et al. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist 2012;17(9):1163-1170
  15. Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, et al. Chemotherapy